On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osi
mertinib for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent.
Read the
FDA announcement.
Read
AstraZeneca's announcement.
Posted 12/21/2020